Drug Profile
Research programme: immuno-oncology therapeutics - Second Genome
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Second Genome
- Developer Mayo Clinic; Second Genome
- Class Antineoplastics; Bacteria; Peptides; Small molecules
- Mechanism of Action Immunomodulators; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Cancer in USA
- 12 Sep 2018 Early research is ongoing in USA (Second Genome pipeline, September 2018)
- 07 Oct 2014 Second Genome enters into a collaboration with Mayo Clinic Center to support development of therapeutics for multiple disease indications, including colorectal cancer